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Summary We report a case of Brugada syndrome with a high deﬁbrillation threshold (DFT) in
whom a subcutaneous array lead was used to lower the DFT in combination with a transve-
nous right ventricular deﬁbrillation lead. The patient had previously received pacemakerVentricular
ﬁbrillation
implantation due to sick sinus syndrome. An implantable cardioverter deﬁbrillator (ICD) with
a transvenous right ventricular deﬁbrillation lead alone required a high DFT. A subcutaneous
array lead improved deﬁbrillation efﬁcacy in combination with a right ventricular lead. These
data suggest that a subcutaneous array lead facilitates implantation of an effective ICD lead
system in patients requiring a high DFT.
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IntroductionBrugada syndrome (BS) is characterized by coved type
ST-segment elevation in the right precordial electrocardio-
graphy leads (V1—3) and an episode of ventricular ﬁbrillation
(VF) in the absence of acute ischemia, electrolyte abnor-
∗ Corresponding author. Tel.: +81 834 28 4411;
fax: +81 834 29 2579.
E-mail address: hadano echo@hotmail.com (Y. Hadano).
B
i
m
c
w
a
s
a
1878-5409/$ — see front matter © 2009 Japanese College of Cardiology.
doi:10.1016/j.jccase.2009.06.004diology. Published by Elsevier Ireland Ltd. All rights reserved.
alities, or structural heart disease [1]. The only effective
herapy for preventing sudden cardiac death (SCD) of
S patients is implantable cardioverter deﬁbrillator (ICD)
mplantation. Thus, the patients with aborted SCD or docu-
ented VF should be treated by ICD [2].
Use of the biphasic deﬁbrillation waveform and the activean ICD considerably lowers energy requirements, combined
ith a progressive reduction of generator and lead size,
llowing for the use of transvenous ICDs as a treatment
trategy. However, occasional patients have unaccept-
bly excessive deﬁbrillation energy requirements, despite
Published by Elsevier Ireland Ltd. All rights reserved.
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aigure 1 Electrocardiograms before (A) and after (B) the pil
levation appeared in leads V1 and V2, and prolonged atriovent
ppropriate transvenous deﬁbrillation lead position and
odiﬁcation of deﬁbrillation waveform and conﬁguration.
Gradaus et al. reported that excellent deﬁbrillation
hresholds (DFTs) could be obtained with left pectoral subcu-
aneous array leads in addition to transvenous lead systems
onsisting of a right ventricular lead [3]. The present report
escribes a case of BS with a high DFT in whom a subcuta-
eous array lead was used to lower the DFT in combination
ith a transvenous right ventricular deﬁbrillation lead.
ase report
60-year-old man was admitted to our hospital with
ocumented out-of-hospital VF. The patient had received
acemaker implantation due to sick sinus syndrome at the
ge of 36 years. Left ventricular wall motion and wall
hickness were normal by an echocardiogram. A left ven-
riculogram showed normal contractility with no wall motion
bnormality, and a coronary arteriogram showed intact coro-
ary arteries. A pilsicainide challenge test revealed coved
ype ST-segment elevation in leads V1 and V2 and diagnosed
S (Fig. 1). Programmed ventricular stimulation induced
F. Therefore, the patient underwent left pectoral implan-
ation of an active can ICD (VENTAK PRIZM 2 DR model
861; Guidant Corporation, Boston, MA, USA) with a transve-
ous right ventricular lead system (ENDOTAK ENDURANCE EZ
odel 0154; Guidant Corporation). The endocardial deﬁbril-
ation lead was introduced into the left subclavian vein using
he Seldinger technique, and was positioned in the right ven-
ricular apex under ﬂuoroscopic guidance. In the DFT testing
rocedure, VF was induced using a T-wave shock. Deﬁbrilla-
ion failed with both 21 J or 31 J. A 360-J external shock was
elivered using epicutaneous self-adhesive patches and a
recharged ordinary external deﬁbrillator, and could restore
he basic rhythm. After reversing the polarity of the coil
ead and conﬁrming the lead position by ﬂuoroscopy, the DFT
emained >31 J. An ICD with a transvenous right ventricular
eﬁbrillation lead alone required a high DFT. The decision
as made to enhance the existing system with the addition
d
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snide challenge test. After pilsicainide, coved type ST-segment
ar interval in AAI pacing was further prolonged.
f a subcutaneous array lead (ENDOTAK SQ lead array model
049; Cardiac Pacemakers, Inc., St. Paul, MN, USA) to lower
he DFT. This lead consisted of three electrically common
ultiﬁlar coil elements that comprised a single lead with an
ffective surface area of 39 cm2. This procedure was per-
ormed as physician’s manual under general anesthesia in
he operating room, after seven days. A short skin incision
erpendicular to the ribs was made in the anterior-axillary
ine. The array lead was inserted through the left anterior-
xillary incision and was positioned in the left lateral chest
sing a lead tunneler and sheaths (Fig. 2). The array lead
erminal was tunneled subcutaneously to the ICD generator
ocket and was attached to the ICD generator. The system
as tested using the subcutaneous array lead and the prox-
mal coil of the right ventricular lead as the anode and the
istal coil of the right ventricular lead as the cathode. Both
he ﬁrst and the second induced VF were successfully con-
erted with 21 J. The measured impedance was 40 ohms at
ach deﬁbrillation. Deﬁbrillation energy requirement was
arkedly reduced following the addition of the subcuta-
eous array lead. The ICD system with the subcutaneous
rray lead provided an adequate deﬁbrillation safety margin
f 10 J. Therefore, we did not attempt the lower deﬁbrilla-
ion output below 21 J. The implantation procedure was well
olerated and involved only two incisions for the insertion of
he entire lead system. There were no postoperative com-
lications. The patient was followed up every three months,
ith no events noted.
iscussion
CDs terminate ventricular tachycardia (VT) and VF with high
fﬁcacy and reduce the rate of SCD in patients with fatal
rrhythmias [4]. Following the introduction of transvenous
eﬁbrillation leads, implantation of ICDs was further simpli-
ed by the active can ICD concept. In a multicenter study,
8% of patients could be successfully implanted with the
ctive can system using biphasic shocks [5]. Nevertheless, a
ufﬁciently low DFT cannot be obtained in 2% of patients.
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RFigure 2 Chest radiographs on admission (A) and after implant
lead system and a three-ﬁnger subcutaneous array lead (B). Th
right ventricular apex. The subcutaneous array lead is positione
Herein, we describe a case of BS in whom a subcutaneous
array lead resulted in a marked reduction in deﬁbrillation
energy requirements and no complications. ICD implanta-
tion can be performed successfully using a transvenous
lead system in the majority of patients with BS. Patients
with BS are sometimes complicated with bradyarrhythmia,
such as sick sinus syndrome or atrioventricular block [6].
Although we did not perform the genetic analysis of BS, a
pilsicainide challenge test documented BS. Thus, sick sinus
syndrome may be part of manifestation of genetic BS in the
patient.
The possible mechanisms of a high DFT in this case are
old abandoned pacemaker leads and some characteristic
abnormalities of BS. A transvenous right ventricular deﬁbril-
lation lead might be placed only in the ineffective position
of the right ventricle due to abandoned leads for an upgrade
from a pacemaker to an ICD. In BS, electrophysiologic abnor-
malities: the area of conduction delay and the site of high
inducibility of VF are believed to exist in the right ventricular
outﬂow tract region [7]. The deﬁbrillation shocks were uni-
formly delivered between the endocardial lead at the right
ventricular apex and the active can in the left subclavicu-
lar region of the anterior chest. However, adequate current
density in the right ventricular outﬂow tract may be nec-
essary to produce adequate deﬁbrillation. Watanabe et al.
reported the characteristics of short ventricular ﬁbrillation
cycle length (VFCL) in BS [8]. Since previous studies have
shown that DFT is negatively correlated with VFCL, short
VFCL might be an alternative explanation for high DFT [9].
Therefore, an ICD with a transvenous right ventricular deﬁb-
rillation lead alone might have a very high DFT and an unsafe
device function.
Options for the management of high DFTs include the use
of a high-output device (at present amaximum of 36 J), addi-
tion of a subcutaneous array lead, or adjustment to the tilt
of the biphasic waveform [10]. However, the use of a high-
output device alone was not enough to obtain an adequate
DFT in 48% of patients who required modiﬁcations [11], and
in this case it was unable to provide an adequate deﬁbril-
lation safety margin (>10 J). Adjustment to the tilt of the
biphasic waveform is a viable option for managing high DFTs
in some patients. However, not all device manufacturers
allow this option and head-to-head comparisons of speciﬁc
tilt conﬁgurations have not demonstrated an ideal ‘‘one size
ﬁts all’’ conﬁguration.cardioverter deﬁbrillator (ICD) implantation using a transvenous
ansvenous right ventricular deﬁbrillation lead is placed in the
ng the lateral aspect of the left chest to the posterior area.
The addition of a subcutaneous array lead is a com-
on strategy for lowering the DFT [10], and it has been
hown in a previous study that the subcutaneous array lead
an signiﬁcantly lower the DFT when added to an existing
ransvenous conﬁguration [3]. Therefore, we used the sub-
utaneous array lead, which improved deﬁbrillation efﬁcacy.
t probably can be attributed to the larger deﬁbrillation sur-
ace area and improved deﬁbrillation ﬁeld geometry due to
ore homogenous current within the heart [12].
Additionally, a reduced DFT offers the main advantage
hat the charge time will be markedly shortened if the shock
ecessary to terminate VT/VF is below 30—36 J. Hence, the
ncidence of syncopal events, which is as high as 15% of
atients if the ﬁrst shock is programmed to a maximum of
4 J, can be reduced [13]. Furthermore, the maximum out-
ut of the device can be reduced with a further decrease
n its size and weight, or longevity can be improved. Thus,
mplantation of an extra subcutaneous array lead might be
n option in patients with frequent syncopal events due
o VT/VF despite ICD therapy to reduce the DFT and the
harging time.
In the present case, we did not perform the DFT testing
ust before the addition of a subcutaneous array lead. Even if
e did and an ICD with a transvenous right ventricular deﬁb-
illation lead alone terminated VF, this ICD system cannot
lways terminate VF. Condition of the patient and medica-
ion were unchanged between implantation of a transvenous
eﬁbrillation lead system and addition of a subcutaneous
rray lead. Therefore, it is suggested that a subcutaneous
rray lead improved deﬁbrillation efﬁcacy.
In conclusion, the novel subcutaneous array lead
pproach described in the present case facilitates implanta-
ion of an effective ICD lead system in patients requiring a
igh DFT. The subcutaneous array lead is a promising adjunct
o a transvenous lead system in cases where the DFT with
he transvenous lead alone is unacceptable.
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